Did you use Dupixent to treat a skin condition such as eczema or atopic dermatitis, and later receive a diagnosis of Cutaneous T-Cell Lymphoma (CTCL)? You may be entitled to compensation. Find out today if your case qualifies.

 At Garn & Graber, we are investigating whether the use of Dupixent for conditions such as eczema or atopic dermatitis—and any associated risks or inadequate warnings regarding its potential adverse effects—may be linked to the development of Cutaneous T-Cell Lymphoma (CTCL).

These circumstances have led to complex medical treatment, substantial impacts on health and quality of life, and additional complications associated with the disease.

You may qualify if:

• You used Dupixent to treat a skin condition.
• You were subsequently diagnosed with Cutaneous T-Cell Lymphoma (CTCL).
• This condition has impacted your health or required medical treatment.

Every case is reviewed individually.

If you believe you may have been harmed by your use of Dupixent, contact us today for a free and confidential case evaluation.